Development of an asthma vaccine: research into BCG.
Asthma is an atopic disorder characterised by the activation and recruitment of eosinophils to the lung resulting in chronic swelling and inflammation of the airways. Allergic disorders such as atopic asthma and dermatitis have been increasingly prevalent in developed countries, and the inverse correlation between exposure to major diseases such as tuberculosis and atopy prevalence has been reported. Intranasal administration of Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) has been demonstrated to suppress airway eosinophilia in a model of atopic asthma. This immunomodulation is attributed to the ability of interferon (IFN)-gamma produced by BCG-specific T(H)1 lymphocytes to inhibit the development of lung T(H)2 responses such as airway eosinophilia. The mechanism of IFNgamma-induced inhibition is yet to be defined, but could involve activation of macrophages, direct suppression of developing T(H)2 lymphocytes, or altered dendritic cell activation and antigen presentation. Mycobacteria such as BCG and certain mycobacterial fractions are strong inducers of a T(H)1 immune response. The effectiveness of BCG in inhibiting atopic airway eosinophilia suggests its potential as a useful therapeutic agent in the treatment of atopic asthma.
Scanga
C B
CB
Malaghan Institute of Medical Research, Wellington South, New Zealand. cbscanga@malaghan.org.nz
Le Gros
G
G
D001249:Asthma / Q000628:therapy*; D001500:BCG Vaccine / Q000627:therapeutic use*; D006801:Humans; D007371:Interferon-gamma / Q000502:physiology; D018418:Th2 Cells / Q000502:physiology
D001500:BCG Vaccine; D007371:Interferon-gamma